Drug intelligence / Profile preview

PECS-201

Development stage: Preclinical
Lead developer: Phytecs
Modality: Small Molecules

Overview

PECS-201 is a preclinical-stage botanical formulation developed by Phytecs Pharm, designed to modulate the endocannabinoid system (ECS). It consists of a combination of naturally occurring phytocannabinoids. The therapeutic focus for PECS-201 is broad, encompassing neuropsychiatric disorders such as anxiety, psychosis, obsessive-compulsive disorder (OCD), and schizophrenia, as well as neurological conditions like epilepsy and chronic pain. Additionally, it is being investigated for inflammatory skin diseases, including dermatitis, psoriasis, atopic eczema, and acne, as well as general inflammation. Phytecs Pharm utilizes a network of international academic partners, including the University of São Paulo and the European Brain Research Institute, to support the development of its ECS-targeted pipeline.

Beyond the preview

Go deeper on PECS-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PECS-201.

Explore the full profile